ISTANBUL, Turkey--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today presentation of updated clinical data on ZIO-101 at the European Society of Medical Oncology meeting in Istanbul. The safety and dose-ranging study provides substantial evidence of clinical activity in a variety of solid tumors. The Company believes that these results warrant an expanded phase II program in solid tumors in addition to the recently announced phase II trial program in hematologic cancers.
